<DOC>
	<DOC>NCT01425723</DOC>
	<brief_summary>The primary objective of the study is to evaluate the long-term safety of rFIXFc in participants with hemophillia B. The secondary objective of this study is to evaluate the efficacy of rFIXFc in the prevention and treatment of bleeding episodes.</brief_summary>
	<brief_title>Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B</brief_title>
	<detailed_description>Participants will follow either a prophylaxis or on-demand regimen. The starting dose in this study will be determined by the clinical profile of the patient in the preceding studies, B-LONG 998HB102 (NCT01027364) and Kids B-LONG study 9HB02PED (NCT01440946)</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Key Subjects who have completed studies 998HB102 (NCT01027364) or 9HB02PED (NCT01440946) or other studies with rFIXFc Ability to understand the purposes &amp; risks of the study and provide signed and dated informed consent. Key Hightiter inhibitor (&gt;/=5.00 BU/mL) NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>B-LONG</keyword>
	<keyword>B-YOND</keyword>
	<keyword>B-LONG Extension</keyword>
	<keyword>rFIXFc</keyword>
	<keyword>Severe Hemophilia B</keyword>
</DOC>